Sakari Hietanen
sakari.hietanen@utu.fi |
Publications
- Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrencePembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors (2025)
- Gynecologic OncologyJournal of Clinical Oncology
(A1 Refereed original research article in a scientific journal) - HR-SC—an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib. (2025)
- ESMO OpenJAMA Network Open
(A1 Refereed original research article in a scientific journal) - Beyond HRD status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer (2024)
- Cancer Research Communications
(A1 Refereed original research article in a scientific journal) - Deciphering cancer genomes with GenomeSpy : a grammar-based visualization toolkitComorbidity of Urogynecological and Gastrointestinal Disorders in Female Patients With Lichen Sclerosus (2024)
- GigaScience
(A1 Refereed original research article in a scientific journal) - Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer : Results from the PRIMA/ENGOT-OV26/GOG-3012 trialReal-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study (2024)
- Gynecologic OncologyActa Oncologica
(A1 Refereed original research article in a scientific journal) - Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrenceCirculating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma (2024)
- Translational Oncology
(A1 Refereed original research article in a scientific journal) - Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma (2024)
- BMC CancerCancer Cell
(A1 Refereed original research article in a scientific journal) - HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma (2024)
- Gynecologic OncologyJournal of Lower Genital Tract DiseaseInternational Journal of Gynecological Cancer
(A1 Refereed original research article in a scientific journal) - Is it safe to operate selected low-risk endometrial cancer patients in secondary hospitals?Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial (2024)
- EJSO - European Journal of Surgical OncologyEuropean Journal of Cancer
(A1 Refereed original research article in a scientific journal) - Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations (2024)
(A1 Refereed original research article in a scientific journal) - Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial (2024)
- International Journal of Gynecological Cancer
(A1 Refereed original research article in a scientific journal) - (2024)
(A1 Refereed original research article in a scientific journal) - Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study (2024)
- Acta Oncologica
(A1 Refereed original research article in a scientific journal) - (2024)
(A1 Refereed original research article in a scientific journal) - (2023)
- Biomedicine and Pharmacotherapy
(A1 Refereed original research article in a scientific journal) - (2023)
(A1 Refereed original research article in a scientific journal) - 2023
(A1 Refereed original research article in a scientific journal) - Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma (2023)
(A1 Refereed original research article in a scientific journal) - Evolutionary study identifies poor prognosis HGSC patients and reveals clinically relevant targets at diagnosis and relapse (2023)
(Other publication) - Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes (2023)
- Clinical Cancer Research
(A1 Refereed original research article in a scientific journal)